Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

(2022) Nicholas I Paton et al.   Lancet HIV

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

(2022) Guan-Jhou Chen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis

(2022) Maria Mazzitelli et al.   Biomedicines

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance

(2021) Nokuzola Mbhele et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV

(2021) I-Wen Chen et al.   Infectious Diseases and Therapy

Transmitted Drug Resistance Among HIV-1 Diagnoses in the United States, 2014–2018

(2021) R Paul McClung et al.   CLINICAL INFECTIOUS DISEASES

Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV

(2021) Yu-Lin Lee et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

(2021) Nicholas I. Paton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance

(2020) Rima K. Acosta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

(2019) Michael Aboud et al.   LANCET INFECTIOUS DISEASES

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

(2019) Kristen Andreatta et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

(2018) Emma D. Deeks   DRUGS

Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013–2014

(2017) Rachel A Silverman et al.   JOURNAL OF INFECTIOUS DISEASES

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

(2017) Nicholas I Paton et al.   Lancet HIV

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

(2016) John Gregson et al.   LANCET INFECTIOUS DISEASES

Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD)

(2016) Claudia Reinheimer et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study

(2016) Alberto M La Rosa et al.   Lancet HIV

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

(2015) Mark A Boyd et al.   Lancet HIV

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

(2015) Jean-Michel Molina et al.   Lancet HIV

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance

(2014) Scott Garforth et al.   Viruses-Basel

International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase

(2010) P. M. Grant et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria

(2009) Claudia A Hawkins et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES